DOCSLIB.ORG

3.2.2 Serotonin Reuptake Inhibitors and Persistent Sexual Dysfunction

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
3.2.2 Serotonin Reuptake Inhibitors and Persistent Sexual Dysfunction Serotonin reuptake inhibitors and persistent sexual dysfunction after discontinued CONFIDENTIAL treatment Medicines Adverse Reactions Committee Meeting date 12/09/2019 Agenda item 3.2.2 Title Serotonin reuptake inhibitors and persistent sexual dysfunction after discontinued treatment Submitted by Medsafe Pharmacovigilance Paper type For advice Team Active ingredient Product name Sponsor SSRIs Citalopram Cipramil Pharmacy Retailing (New Zealand) Limited t/a Healthcare Logistics Citalopram PSM Healthcare Limited t/a API Consumer Brands Escitalopram Escitalopram Air Flow Products Limited Lexapro Pharmacy Retailing (New Zealand) Limited t/a Healthcare Logistics Loxalate Mylan New Zealand Limited Fluoxetine Arrow-Fluoxetine Teva Pharma (New Zealand) Limited Arrow-Fluoxetine Dispersible Teva Pharma (New Zealand) Limited Fluoxetine-AFT AFT Pharmaceuticals Limited Prozac 20 Eli Lily and Company (New Zealand) Limited Paroxetine Apo-Paroxetine Apotex New Zealand Limited Aropax GlaxoSmithKline (New Zealand) Limited Loxamine Mylan New Zealand Limited Sertraline Arrow-Sertraline Teva Pharma (New Zealand) Limited Setrona Douglas Pharmaceuticals Limited Zoloft Pfizer New Zealand Limited SNRIs Venlafaxine Arrow-Venlafaxine Teva Pharma (New Zealand) Limited Efexor-XR Pfizer New Zealand Limited Enlafax-XR Mylan New Zealand Limited PHARMAC Products funded by PHARMAC and on the Hospital Medicines List (in bold) funding Previous MARC None meetings International EMA action PRAC meeting on 13-16 May 2019 – Having considered the available evidence from EudraVigilance, literature, social media and cumulative reviews provided by Marketing Authorisation Holders, product information for SSRIs and SNRIs should be amended to include information on persistent sexual dysfunction after drug withdrawal1. Prescriber Update Sexual dysfunction associated with antidepressants and antipsychotics – March 20152. Classification Prescription medicine Medicines Adverse Reactions Committee: 12 September 2019 Page 1 of 29 Serotonin reuptake inhibitors and persistent sexual dysfunction after discontinued CONFIDENTIAL treatment Table of Contents 1 PURPOSE ................................................................................................................................................................................................. 4 2 BACKGROUND ...................................................................................................................................................................................... 4 2.1 RxISK study and petition ....................................................................................................................................................... 4 2.2 Serotonin reuptake inhibitors .............................................................................................................................................. 5 2.2.1 Selective serotonin reuptake inhibitors (SSRIs) ....................................................................................................... 5 2.2.2 Serotonin and noradrenalin reuptake inhibitors (SNRIs) .................................................................................... 5 2.3 Persistent sexual dysfunction .............................................................................................................................................. 6 2.4 Data sheets ................................................................................................................................................................................. 6 2.4.1 New Zealand ......................................................................................................................................................................... 6 3 SCIENTIFIC INFORMATION .............................................................................................................................................................. 9 3.1 Published literature.................................................................................................................................................................. 9 3.1.1 Bala et al (2018)32 ................................................................................................................................................................ 9 3.1.2 Coskuner et al (2017)33 .................................................................................................................................................... 10 3.1.3 Reisman (2017)34................................................................................................................................................................ 11 3.2 International ................................................................ 12 3.2.1 .......................................................................................................... 12 3.2.2 ............................................................................................................ 12 3.2.3 ................................................................................................................................................. 14 3.2.4 ......................................................... 14 3.2.5 ............................................................................................ 15 3.2.6 .................................................................................................................................................................... 16 3.3 Further action from the FDA, EMA and MHRA ........................................................................................................... 16 3.3.1 EMA ......................................................................................................................................................................................... 16 3.4 Company reports .................................................................................................................................................................... 17 3.4.1 GlaxoSmithKline (New Zealand) Limited – Aropax (paroxetine) (Annexe 1).............................................. 17 3.4.2 Lundbeck on behalf of Pharmacy Retailing (New Zealand) Limited trading as Healthcare Logistics – Cipramil (citalopram) (Annexe 2) ............................................................................................................................................. 18 3.4.3 Pfizer New Zealand Limited – Zoloft (sertraline) (Annexe 3) ........................................................................... 19 3.5 CARM data (Annexe 5) ......................................................................................................................................................... 22 3.6 ADIS Insight35 ........................................................................................................................................................................... 23 4 DISCUSSION AND CONCLUSIONS ............................................................................................................................................. 26 5 ADVICE SOUGHT ............................................................................................................................................................................... 27 6 ANNEXES .............................................................................................................................................................................................. 27 7 REFERENCES ........................................................................................................................................................................................ 27 Medicines Adverse Reactions Committee: 12 September 2019 Page 3 of 29 Serotonin reuptake inhibitors and persistent sexual dysfunction after discontinued CONFIDENTIAL treatment 1 PURPOSE In May 2018, Medsafe received an email from RxISK highlighting a study they had recently published in the International Journal of Risk and Safety in Medicine regarding persistent sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin4. A petition was also attached which has been submitted to the Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Medicines and Healthcare products Regulatory Agency (MHRA), requesting changes to product information5. The purpose of this paper is to review the risk of persistent sexual dysfunction after discontinued treatment with serotonin reuptake inhibitors (SRIs). 2 BACKGROUND 2.1 RxISK study and petition The objective of the RxISK study was to investigate clinical reports of post-selective serotonin reuptake inhibitors (SSRI) sexual dysfunction, post-finasteride syndrome and persisting sexual dysfunction following antidepressants, 5α-reductase inhibitors and isotretinoin4. RxISK.org is an independent drug safety website set up by the authors and colleagues, offering an adverse event reporting facility which began collecting data on all drugs and all adverse events in 20124. Data from RxISK was used to establish the clinical features, demographic details and clinical trajectories of syndromes of persistent sexual difficulties following three superficially different treatment modalities4. The study reported on 300 cases of persisting sexual dysfunction from 37 countries following 14 different drugs comprised of serotonin reuptake inhibiting antidepressants, 5α-reductase inhibitors and isotretinoin4. While reports
Load more

Recommended publications
  • Hypersexuality in Neurological Disorders
    HYPERSEXUALITY IN NEUROLOGICAL DISORDERS NATALIE AHMAD MAHMOUD TAYIM A thesis submitted to the Institute of Neurology in fulfilment of the requirements for the degree of Doctor of Philosophy (PhD) University College London January 2019 Declaration of originality I, Natalie Ahmad Mahmoud Tayim, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. _________________________________ Natalie Ahmad Mahmoud Tayim ii Abstract The issue of hypersexuality in neurological disorders is grossly underreported. More research has been done into sexual dysfunction (outside of hypersexuality) in neurological disorders such as erectile dysfunction and hyposexuality (loss of libido). Furthermore, in Parkinson’s disease research, most mention of hypersexuality has been in conjunction with other impulse control disorders and has therefore not been examined in depth on its own. Although in recent years hypersexuality has become more recognized as an issue in research, there is still very limited information regarding its manifestations, impact, and correlates. It is therefore important to explore this area in detail in order to broaden understanding associated with this sensitive issue. Perhaps in doing so, barriers will be broken and the issue will become more easily discussed and, eventually, more systematically assessed and better managed. This thesis aims to serve as an exploratory paper examining prevalence, clinical phenomenology, impact, and potential feasible psychological interventions for hypersexuality in patients with neurological disorders and their carers. The thesis is divided into three main studies: 1. Study I: systematic review assessing prevalence, clinical phenomenology, successful treatment modalities, implicated factors contributing to the development, and assessment tools for hypersexuality in specific neurological disorders.
    [Show full text]
  • Physiology of Female Sexual Function and Dysfunction
    International Journal of Impotence Research (2005) 17, S44–S51 & 2005 Nature Publishing Group All rights reserved 0955-9930/05 $30.00 www.nature.com/ijir Physiology of female sexual function and dysfunction JR Berman1* 1Director Female Urology and Female Sexual Medicine, Rodeo Drive Women’s Health Center, Beverly Hills, California, USA Female sexual dysfunction is age-related, progressive, and highly prevalent, affecting 30–50% of American women. While there are emotional and relational elements to female sexual function and response, female sexual dysfunction can occur secondary to medical problems and have an organic basis. This paper addresses anatomy and physiology of normal female sexual function as well as the pathophysiology of female sexual dysfunction. Although the female sexual response is inherently difficult to evaluate in the clinical setting, a variety of instruments have been developed for assessing subjective measures of sexual arousal and function. Objective measurements used in conjunction with the subjective assessment help diagnose potential physiologic/organic abnormal- ities. Therapeutic options for the treatment of female sexual dysfunction, including hormonal, and pharmacological, are also addressed. International Journal of Impotence Research (2005) 17, S44–S51. doi:10.1038/sj.ijir.3901428 Keywords: female sexual dysfunction; anatomy; physiology; pathophysiology; evaluation; treatment Incidence of female sexual dysfunction updated the definitions and classifications based upon current research and clinical practice.
    [Show full text]
  • Sexual Disorders and Gender Identity Disorder
    CHAPTER :13 Sexual Disorders and Gender Identity Disorder TOPIC OVERVIEW Sexual Dysfunctions Disorders of Desire Disorders of Excitement Disorders of Orgasm Disorders of Sexual Pain Treatments for Sexual Dysfunctions What are the General Features of Sex Therapy? What Techniques Are Applied to Particular Dysfunctions? What Are the Current Trends in Sex Therapy? Paraphilias Fetishism Transvestic Fetishism Exhibitionism Voyeurism Frotteurism Pedophilia Sexual Masochism Sexual Sadism A Word of Caution Gender Identity Disorder Putting It Together: A Private Topic Draws Public Attention 177 178 CHAPTER 13 LECTURE OUTLINE I. SEXUAL DISORDERS AND GENDER-IDENTITY DISORDER A. Sexual behavior is a major focus of both our private thoughts and public discussions B. Experts recognize two general categories of sexual disorders: 1. Sexual dysfunctions—problems with sexual responses 2. Paraphilias—repeated and intense sexual urges and fantasies to socially inappropri- ate objects or situations C. In addition to the sexual disorders, DSM includes a diagnosis called gender identity dis- order, a sex-related pattern in which people feel that they have been assigned to the wrong sex D. Relatively little is known about racial and other cultural differences in sexuality 1. Sex therapists and sex researchers have only recently begun to attend systematically to the importance of culture and race II. SEXUAL DYSFUNCTIONS A. Sexual dysfunctions are disorders in which people cannot respond normally in key areas of sexual functioning 1. As many as 31 percent of men and 43 percent of women in the United States suffer from such a dysfunction during their lives 2. Sexual dysfunctions typically are very distressing and often lead to sexual frustra- tion, guilt, loss of self-esteem, and interpersonal problems 3.
    [Show full text]
  • Sexual Dysfunction and Related Factors in Pregnancy
    Banaei et al. Systematic Reviews (2019) 8:161 https://doi.org/10.1186/s13643-019-1079-4 PROTOCOL Open Access Sexual dysfunction and related factors in pregnancy and postpartum: a systematic review and meta-analysis protocol Mojdeh Banaei1, Maryam Azizi2, Azam Moridi3, Sareh Dashti4, Asiyeh Pormehr Yabandeh3 and Nasibeh Roozbeh3* Abstract Background: Sexual dysfunction refers to a chain of psychiatric, individual, and couple’s experiences that manifests itself as a dysfunction in sexual desire, sexual arousal, orgasm, and pain during intercourse. The aim of this systematic review will be to assess the sexual dysfunction and determine the relevant factors to sexual dysfunction during pregnancy and postpartum. Methods and analysis: All observational studies, including descriptive, descriptive-analytic, case-control, and cohort studies published between 1990 and 2019, will be included in the study. Review articles, case studies, case reports, letter to editors, pilot studies, and editorial will be excluded from the study. The search will be conducted in the Cochrane Central Register, MEDLINE, Google Scholar, EMBASE, ProQuest, Scopus, WOS, and CINAHL databases. Eligible studies should assess at least one of the sexual dysfunction symptoms in pregnant women orinthefirstyearpostpartum.Quality assessment of studies will be performed by two authors independently based on the NOS checklist. This checklist is designed to assess the quality of observational studies. Data will be analyzed using Stata software ver. 11. Considering that the index investigated in the present study will be the level of sexual disorder, standard error will be calculated for each study using binomial distribution. The heterogeneity level will be investigated using Cochran’sQstatisticandI2 index in a chi-square test at a significance level of 1.1.
    [Show full text]
  • Erectile Dysfunction and Premature Ejaculation
    GUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation (Text update April 2014) K. Hatzimouratidis (chair), I. Eardley, F. Giuliano, D. Hatzichristou, I. Moncada, A. Salonia, Y. Vardi, E. Wespes Eur Urol 2006 May;49(5):806-15 Eur Urol 2010 May;57(5):804-14 Eur Urol 2012 Sep;62(3):543-52 ERECTILE DYSFUNCTION Definition, epidemiology and risk factors Erectile dysfunction (ED) is the persistent inability to attain and maintain an erection sufficient to permit satisfactory sex- ual performance. Although ED is a benign disorder, it affects physical and psychosocial health and has a significant impact on the quality of life (QoL) of sufferers and their partners. There is increasing evidence that ED can be an early mani- festation of coronary artery and peripheral vascular disease; thus, ED should not be regarded only as a QoL issue but also as a potential warning sign of cardiovascular disease includ- ing lack of exercise, obesity, smoking, hypercholesterolaemia, and the metabolic syndrome. The risk of ED may be reduced by modifying these risk factors, particularly taking exercise or losing weight. Another risk factor for ED is radical prostatec- tomy (RP) in any form (open, laparoscopic, or robotic) because of the risk of cavernosal nerve injury, poor oxygenation of the corpora cavernosa, and vascular insufficiency. 130 Male Sexual Dysfunction Diagnosis and work-up Basic work-up The basic work-up (minimal diagnostic evaluation) outlined in Fig. 1 must be performed in every patient with ED. Due to the potential cardiac risks associated with sexual activity, the three Princeton Consensus Conference stratified patients with ED wanting to initiate, or resume, sexual activity into three risk categories.
    [Show full text]
  • Background Note on Human Rights Violations Against Intersex People Table of Contents 1 Introduction
    Background Note on Human Rights Violations against Intersex People Table of Contents 1 Introduction .................................................................................................................. 2 2 Understanding intersex ................................................................................................... 2 2.1 Situating the rights of intersex people......................................................................... 4 2.2 Promoting the rights of intersex people....................................................................... 7 3 Forced and coercive medical interventions......................................................................... 8 4 Violence and infanticide ............................................................................................... 20 5 Stigma and discrimination in healthcare .......................................................................... 22 6 Legal recognition, including registration at birth ............................................................... 26 7 Discrimination and stigmatization .................................................................................. 29 8 Access to justice and remedies ....................................................................................... 32 9 Addressing root causes of human rights violations ............................................................ 35 10 Conclusions and way forward..................................................................................... 37 10.1 Conclusions
    [Show full text]
  • Arousing Imaginations
    Evolutionary Psychology www.epjournal.net – 2007. 5(4): 778-785 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Book Review Arousing Imaginations A review of Michael R. Kauth, (Ed.), Handbook of the Evolution of Human Sexuality, Haworth Press, Binghamton, NY, 2006, 395 pp., $50.00 (softbound), $130.00 (hardbound) Reviewed by David Puts, Ph.D. Department of Anthropology, 424 Carpenter Building, Pennsylvania State University, University Park, PA 16802. Email: [email protected] In the quarter century since Donald Symons (1979) wrote The Evolution of Human Sexuality, research in this area has flourished. Michael Kauth’s edited volume Handbook of the Evolution of Human Sexuality (co-published as Volume 18, Numbers 2/3 and 4 2006 of the Journal of Psychology & Human Sexuality) is therefore a welcome addition. Kauth assembles researchers in diverse areas of human sexuality, including heterosexual mate choice, sexual arousal and olfactory preferences, but the focus is heavily upon the evolution and development of homosexuality, with five of the book’s ten chapters centering on this topic. Given that only 2-3% of men and 1-2% of women report predominantly homosexual preferences, this focus may seem disproportionate. However, the volume is intended not to cover all aspects of human sexuality but to serve as a springboard for future research, a mission that it will undoubtedly accomplish. The scholarship in the Handbook is variable but generally good. The content is often heavy on speculation and light on evidence, which would be less concerning if authors acknowledged this more openly. Instead, the chapters of the Handbook often reify “facts” that are still quite theoretical—for example, Kauth’s statement that “physical symmetry and extravagant sexual ornamentation are ‘honest’ signals of health and genetic quality” (p.
    [Show full text]
  • Drug-Induced Sexual Dysfunction in Men and Women
    VOLUME 36 : NUMBER 2 : APRIL 2013 ARTICLE Drug-induced sexual dysfunction in men and women Helen M Conaglen whether the clinician is willing to ask about sexual Clinical psychologist and SUMMARY issues and does so in a sensitive way.7,8 Senior research fellow Many medical conditions and their treatments Patients on long-term medications may not be John V Conaglen aware that their sexual problems have developed Endocrinologist and contribute to sexual dysfunction. as a result of their treatment. Conversely some may Associate professor in Commonly implicated drugs include Medicine blame their drugs for sexual problems which are due Sexual Health Research Unit antihypertensives, antidepressants, to relationship difficulties or other stressors. Some Waikato Clinical School antipsychotics and antiandrogens. doctors consider that asking patients if they had Faculty of Medical and Understanding the potential for drug-induced noticed any sexual adverse effects from their drugs Health Sciences University of Auckland sexual problems and their negative impact may ‘suggest’ them to the patient, and possibly result on adherence to treatment will enable the in non-adherence. Patients attributing their sexual clinician to tailor treatments for the patient problems to their drugs are less likely to continue the Key words treatment even when necessary for their health.9 The antidepressants, and his or her partner. consultation should include discussion of the patient’s antihypertensives, Encouraging a discussion with the patient sexual issues so these can be considered in treatment antipsychotics, arousal, about sexual function and providing erectile dysfunction, decisions. hypoactive sexual desire strategies to manage the problem are critical disorder, male impotence, to good clinical care.
    [Show full text]
  • Delayed Ejaculation & Anorgasmia
    Delayed ejaculation & anorgasmia EMMANUELE A. JANNINI Chair of Endocrinology & Sexual Medicine Tor Vergata University of Rome, Italy It Soc Androl & Sex Med – President-elect Taxonomy of ejaculatory disorders Epidemiology of ejaculatory disorders 25 a) timing 20 – PREMATURE EJACULATION 15 – DELAYED EJACULATION 10 Percentage 5 b) modality 0 E N IA R PE DE IO M AS ‐ RETROGRADE EJACULATION LAT G U R O JAC ‐ ANEJACULATION (impotentia ejaculationis) E AN AN Taxonomy of ejaculatory disorders • EMISSION PHASE DISORDERS: – Retrograde ejaculation • EJACULATION PHASE DISORDERS: – Premature ejaculation – Deficient ejaculation: • Delayed ejaculation • Anejaculation • ORGASM DISORDERS: – Anorgasmia – Postorgasmic illness syndrome Standard Operating Procedures (SOP) in Diagnosis and Treatment of Delayed Ejaculation/Anejaculation ISSM Standards Committee Meeting June 23-25, 2010 Hotel Agneshof Nürnberg, Germany Pierre Assalian Canada Emmanuele A. Jannini Italy Chris G McMahon (Chairman) Australia David Rowland USA Marcel Waldinger (Chairman) The Netherlands DELAYED EJACULATION Delayed ejaculation • Much less frequent than PE • A rare reason for medical help seeking • Underdiagnosed • Undertreated Is DE a disease? • girls are happy… …where is the problem? …but girls are not happy… Why so poor science? • Low prevalence • Few studies • Classically considered A new psychogenic in nature • Classically treated with behavioral therapies challenge • Definition(s) lacking • Etiologies largely unknown for • Pathogenesis obscure • Lack of awareness and Sexual acknowledgements
    [Show full text]
  • The Effect of Contraceptive Implants on Sexual Desire in Women Zoë Tessier and Katrina Armstrong | Faculty of Health Science | University of Ottawa
    Are contraceptives causing the bedroom blues? The effect of contraceptive implants on sexual desire in women Zoë Tessier and Katrina Armstrong | Faculty of Health Science | University of Ottawa ABSTRACT METHODS DISCUSSION Background: In the United States, an estimated 51% of pregnancies are unwanted (Sanders et. al., 2014). High rates of unwanted • The main finding of the structured literature review was a decrease in sexual desire in women using contraceptive implants. pregnancy can be reduced by the use of various contraceptives. Hormonal contraceptives are a popular choice among fertile women PubMed, Medline, and Scopus were searched for relevant However the studies did not provide satisfactory evidence to draw a confident conclusion. and have been shown to effectively prevent pregnancy. Contraceptive implants are a type of progestogen-only birth control. The articles. “Contraceptive implants” and “libido” were initially • The Di Carlo and Sanders articles used the “Female Sexual Function Index” (FSFI) and the “Short Form-36” (SF-36) as a tool to implant is a single rod that is inserted subdermally into the upper arm. It has 68 mg of active compound and is effective in searched under the PubMed database. “Contraception” and measure sexual desire. All other articles failed to explicitly indicate the controls and measures used to determine libido. preventing pregnancy for up to 3 years (Gezginc et. al., 2007). Objective: Examine if contraceptive implants decrease a woman’s “drug implants” combined with “sexual dysfunction” or “libido” • Two articles described an increase in sexual desire while the remaining four reported a decrease. The increases were believed to sexual desire via a literature review.
    [Show full text]
  • Post-Orgasmic Illness Syndrome: a Closer Look
    Indonesian Andrology and Biomedical Journal Vol. 1 No. 2 December 2020 Post-orgasmic Illness Syndrome: A Closer Look William1,2, Cennikon Pakpahan2,3, Raditya Ibrahim2 1 Department of Medical Biology, Faculty of Medicine and Health Sciences, Universitas Katolik Indonesia Atma Jaya, Jakarta, Indonesia 2 Andrology Specialist Program, Department of Medical Biology, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo Hospital, Surabaya, Indonesia 3 Ferina Hospital – Center for Reproductive Medicine, Surabaya, Indonesia Received date: Sep 19, 2020; Revised date: Oct 6, 2020; Accepted date: Oct 7, 2020 ABSTRACT Background: Post-orgasmic illness syndrome (POIS) is a rare condition in which someone experiences flu- like symptoms, such as feverish, myalgia, fatigue, irritabilty and/or allergic manifestation after having an orgasm. POIS can occur either after intercourse or masturbation, starting seconds to hours after having an orgasm, and can be lasted to 2 - 7 days. The prevalence and incidence of POIS itself are not certainly known. Reviews: Waldinger and colleagues were the first to report cases of POIS and later in establishing the diagnosis, they proposed 5 preliminary diagnostic criteria, also known as Waldinger's Preliminary Diagnostic Criteria (WPDC). Symptoms can vary from somatic to psychological complaints. The mechanism underlying this disease are not clear. Immune modulated mechanism is one of the hypothesis that is widely believed to be the cause of this syndrome apart from opioid withdrawal and disordered cytokine or neuroendocrine responses. POIS treatment is also not standardized. Treatments includeintra lymphatic hyposensitization of autologous semen, non-steroid anti-inflamation drugs (NSAIDs), steroids such as Prednisone, antihistamines, benzodiazepines, hormones (hCG and Testosterone), alpha-blockers, and other adjuvant medications.
    [Show full text]
  • Neurogenic Erectile Dysfunction. Where Do We Stand?
    medicines Review Neurogenic Erectile Dysfunction. Where Do We Stand? Charalampos Thomas 1,* and Charalampos Konstantinidis 2 1 Urology Department, General Hospital of Corinth, 20131 Corinth, Greece 2 Urology & Neurourology Unit, National Rehabilitation Center, Ilion, 13122 Athens, Greece; [email protected] * Correspondence: [email protected] Abstract: Erectile Dysfunction (ED) is the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance, causing tremendous effects on both patients and their partners. The pathophysiology of ED remains a labyrinth. The underlying mechanisms of ED may be vasculogenic, neurogenic, anatomical, hormonal, drug-induced and/or psychogenic. Neurogenic ED consists of a large cohort of ED, accounting for about 10% to 19% of all cases. Its diversity does not allow an in-depth clarification of all the underlying mechanisms nor a “one size fits all” therapeutical approach. In this review, we focus on neurogenic causes of ED, trying to elucidate the mechanisms that lie beneath it and how we manage these patients. Keywords: erectile dysfunction (ED); neurogenic; sexual dysfunction (SD); phosphodiesterase type-5 inhibitors (PDE5I); spinal cord injury (SCI); multiple sclerosis (MS) 1. Introduction Erectile dysfunction (ED) is defined as the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance [1]. Besides the obvious, it has tremendous effects on the patient’s psychosocial health, and it affects not only their quality of life but the lives of their partners [2]. Citation: Thomas, C.; Konstantinidis, The pathophysiology of ED remains a labyrinth since many pathways can co-exist, C. Neurogenic Erectile Dysfunction. thus contributing negatively. Where Do We Stand? Medicines 2021, Traditionally ED was divided into three large cohorts, organic, psychogenic and of 8, 3.
    [Show full text]